Connect your cancer research with cancer patients, their family and friends. Funding decisions are made by our cancer survivor community.
Get an “insider” look into what is actually going on with your money. You control which research project gets your donation.
Hormone therapy for prostate cancer only works for a short time and makes men tired, impotent, depressed and fat. We have learned that treatment of hormone-resistant prostate cancer with high doses of testosterone can stop the growth of prostate cancer and makes men feel great and are seeking funds to study and test this concept further.
Can administration of HPV vaccine, which can boost wide HPV immunity, lower (HPV) virus load in tissue and then when followed by infra-red coagulation (IRC) treatment of biopsy proven anal precancer lesions decrease risk for precancer recurrences when compared to IRC alone?
What do doctors from around the world think prostate cancer patients need to know (and not know) about androgen deprivation therapy (=hormonal therapy) and its side effects when they start on this treatment? Following a pilot study in Canada, we plan to answer this question via an online survey for physicians who prescribe ADT to prostate cancer patients.
Diabetic patients with prostate cancer taking metformin or another class of anti-insulin resistance drugs (thiazolidinediones) live longer than those who don’t. Obesity (a major cause of diabetes) enhances prostate cancer aggressiveness through insulin, insulin-like growth factor-1 and substances secreted by fat cells. This project is to find out how and why these drugs can stop or slow down cancer growth, particularly in the context of obesity.
Medical Nanotechnologies is revolutionizing the way cancer is treated by using heat targeted directly to the tumor. No radiation therapy, no chemotherapy.
This project will develop improve technology to better identify living, prostate cancer cells that are circulating in patients blood stream. This will enable clinicians to monitor the course of disease, such as the disseminated metastasis. Importantly, this technology holds promise to allow clinicians to interrogate response to drugs on the circulating prostate cancer cells directly.
Avodart (dutasteride) commonly used to treat enlarged prostate or benign prostate hyperplasia (BPH) can delay time to metastases and improve survival in patients with rising PSA after initial surgery or radiation for prostate cancer.
As a biomarker, PTEN could have important clinical value. By routinely measuring the status of PTEN in prostate biopsies we may better predict which patients are likely to have high-risk prostate tumors, ones that warrant additional treatment, and choose the best treatment for the individual patient, since a patient’s PTEN status also indicates whether or not his tumor is likely to respond to new “targeted therapies.”
Prostate cancer and breast cancer have many things in common. We plan to study if approved hormonal agents used for breast cancer treatment can be re-purposed to become potent prostate cancer agents.
Abiraterone and enzalutamide are two of the most exciting new oral therapies for men with advanced prostate cancer. This project will use blood samples from patients to determine ahead of time who might respond (and who might not respond) to abiraterone and enzalutamide. This will be done by collecting and analyzing prostate cancer cells from the bloodstream, which we call a "liquid biopsy".
We will generate new radiotherapeutic agents, based on imaging agents we have pioneered over the last decade, to treat metastatic prostate cancer - with a focus on micrometastases that elude all current therapies.
Our previous animal studies identified two bioactive agents that had potent anti-growth and anti-metastasis activities with minimal side effects. In this proposal, we will apply a clinically relevant animal model for hormone-refractory prostate cancer to evaluate the efficacy and safety of the combination of those two bioactive agents in delaying the progression and metastasis that are induced by androgen ablation treatment.
Many men with PSA screen detected low risk prostate cancers undergo needless surgery or radiation both of which carry side effects (incontinence, sexual dysfunction). Men chose to undergo these treatments as the accuracy of clinical classification of disease is modest. Thus a patient may be informed that he has low risk disease but at surgery it is found that the disease is more extensive. Patients thus opt for treatment to be "on the safe side."We would like to use a new technology (Nanostring Counter) to develop a "genetic signature" that can identify those men who are best candidates for therapy (i.e those at risk for disease progression). Brought to fruition, such a strategy would deliver therapy to those who need it while sparing others the debilitating side-effects of prostatectomy/radiation.
We have developed a new cancer vaccine curative of very late stage cancer in a genetic model. The vaccine builds on our studies of ‘NKT’ cells in patients to lead to a clinical trial.
Intercellular communication maintains normal development. Defects in this communication leads to diseases including cancer. This process is mediated by signaling molecules and direct cell contact.
A study to assess the economic efficiencies of cryotherapy for prostate cancer patients. The protocol will include assessment of cost to the healthcare industry and well as employers and patients.
By leveraging lab-on-a-chip technology, novel biomarkers, and predictive algorithms, Cellanyx will offer a predictive, sensitive, and cost effective solution to inform physicians at the radical prostatectomy decision point. Our platform technology will improve the prostate cancer diagnostic process, increase patient quality of life, and reduce healthcare costs.
We and others have in the past successfully demonstrated that bacteria can also be used as a therapeutic vector to cure prostate tumors in animal models. However, the clinical use of this therapy has been limited – in part because its therapeutic mode of action against tumors is poorly characterized. We seek to fill this knowledge gap for our preferred bacterial model which has demonstrated tumor-targeting and tumor-killing properties.
A pilot clinical trial assessing the impact of teaching qi gong skills to prostate cancer survivors to help improve their quality of life.
Qi gong is a traditional healing method to strengthen the body, mind and spirit.
This study seeks to find the reasons why a group of men with advanced prostate cancer first sought treatment long after they might have been cured. All have passed away; many would be alive today had their cancer been diagnosed earlier. The study analyzes the events leading up to their late diagnoses and seeks to identify modifiable factors that contributed to missed or late diagnoses, with a particular focus on black men, who are disproportionately represented among them.
This will be a pilot study assessing a program to educate patients how to make dietary and lifestyle changes after a prostate cancer diagnosis.
92% of every dollar you donate goes to that cancer project. Compare that with the 16% to 65% that most foundations and government agencies distribute.
Projects by leading and emerging scientists from institutions like Harvard, UCLA, Johns Hopkins, Columbia, MD Anderson and Biotech start-ups. Fund cutting edge research to cure the cancer you are fighting.